OncoCyte Corporation (OCX)
OncoCyte Statistics
Share Statistics
OncoCyte has 28.6M shares outstanding. The number of shares has increased by 113.99% in one year.
| Shares Outstanding | 28.6M |
| Shares Change (YoY) | 113.99% |
| Shares Change (QoQ) | 69.88% |
| Owned by Institutions (%) | 0.34% |
| Shares Floating | 20.06M |
| Failed to Deliver (FTD) Shares | 4.76K |
| FTD / Avg. Volume | 5.56% |
Short Selling Information
The latest short interest is 319.4K, so 1.9% of the outstanding shares have been sold short.
| Short Interest | 319.4K |
| Short % of Shares Out | 1.9% |
| Short % of Float | 2.42% |
| Short Ratio (days to cover) | 4.68 |
Valuation Ratios
The PE ratio is -0.51 and the forward PE ratio is -1.17. OncoCyte's PEG ratio is -0.02.
| PE Ratio | -0.51 |
| Forward PE | -1.17 |
| PS Ratio | 16.54 |
| Forward PS | 6.3 |
| PB Ratio | -2.53 |
| P/FCF Ratio | -1.5 |
| PEG Ratio | -0.02 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for OncoCyte.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.62, with a Debt / Equity ratio of -0.3.
| Current Ratio | 1.62 |
| Quick Ratio | 1.56 |
| Debt / Equity | -0.3 |
| Debt / EBITDA | -0.06 |
| Debt / FCF | -0.18 |
| Interest Coverage | -726.68 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $40.89K |
| Profits Per Employee | $-1.32M |
| Employee Count | 46 |
| Asset Turnover | 0.05 |
| Inventory Turnover | 2.78 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -1.68% in the last 52 weeks. The beta is 0.98, so OncoCyte's price volatility has been higher than the market average.
| Beta | 0.98 |
| 52-Week Price Change | -1.68% |
| 50-Day Moving Average | 2.94 |
| 200-Day Moving Average | 2.84 |
| Relative Strength Index (RSI) | 44.37 |
| Average Volume (20 Days) | 85.59K |
Income Statement
In the last 12 months, OncoCyte had revenue of 1.88M and earned -60.66M in profits. Earnings per share was -4.64.
| Revenue | 1.88M |
| Gross Profit | 740K |
| Operating Income | -61.04M |
| Net Income | -60.66M |
| EBITDA | -59.02M |
| EBIT | -60.58M |
| Earnings Per Share (EPS) | -4.64 |
Balance Sheet
The company has 8.64M in cash and 3.66M in debt, giving a net cash position of 4.97M.
| Cash & Cash Equivalents | 8.64M |
| Total Debt | 3.66M |
| Net Cash | 4.97M |
| Retained Earnings | -350.54M |
| Total Assets | 35.08M |
| Working Capital | 4.48M |
Cash Flow
In the last 12 months, operating cash flow was -20.71M and capital expenditures 0, giving a free cash flow of -20.71M.
| Operating Cash Flow | -20.71M |
| Capital Expenditures | 0 |
| Free Cash Flow | -20.71M |
| FCF Per Share | -1.58 |
Margins
Gross margin is 39.34%, with operating and profit margins of -3245.14% and -3225.04%.
| Gross Margin | 39.34% |
| Operating Margin | -3245.14% |
| Pretax Margin | -3225.04% |
| Profit Margin | -3225.04% |
| EBITDA Margin | -3137.43% |
| EBIT Margin | -3245.14% |
| FCF Margin | -1101.17% |
Dividends & Yields
OCX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for OCX is $4.62, which is 58.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $4.62 |
| Price Target Difference | 58.2% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Stock Splits
The last stock split was on Jul 25, 2023. It was a backward split with a ratio of 1:20.
| Last Split Date | Jul 25, 2023 |
| Split Type | backward |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | -18.49 |
| Piotroski F-Score | 4 |